A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
BioNTech SE
Dana-Farber Cancer Institute
Nationwide Children's Hospital
Roswell Park Cancer Institute
Diakonos Oncology Corporation
University of Florida
Mayo Clinic
University of Birmingham
BPGbio
ZSky Biotech Inc
NRG Oncology
M.D. Anderson Cancer Center
Augusta University
Sun Yat-sen University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Iowa
Case Comprehensive Cancer Center
Stanford University
Dana-Farber Cancer Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Massachusetts General Hospital
Polaris Group
Medical College of Wisconsin
National Institutes of Health Clinical Center (CC)
Emory University
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Mayo Clinic
Washington University School of Medicine
Olympion Medical Center
Duke University
Mayo Clinic
Rigel Pharmaceuticals
Huashan Hospital
Centre Hospitalier Universitaire de Besancon
University of Sydney
Heinrich-Heine University, Duesseldorf
Wake Forest University Health Sciences
Jonsson Comprehensive Cancer Center
JenKem Technology Co., Ltd.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Zhujiang Hospital
Massachusetts General Hospital
Duke University
Candel Therapeutics, Inc.
Meyer Children's Hospital IRCCS
Southern Medical University, China
Beijing Sanbo Brain Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Duke University
Emory University